[PDF] Top 20 Multiple myeloma - a review

... Thalidomide. Thalidomide as a single agent is effective in approximately one third of patients with relapsed myeloma 19,20 . The exact mechanism of action is unknown, but the drug is thought to act directly on ... See full document

... This review identified three journal articles relating to the role of physical activity in the prevention of multiple myeloma, nine papers were identified in the treatment of multiple ... See full document

... Bruton’s tyrosine kinase (BTK) is an enzyme that plays a crucial role in B cell survival and maturation. Ibrutinib, an orally administered selective inhibitor of BTK, has demonstrated impressive efficacy in the treatment ... See full document

... Evidence review: In patients with relapsed and refractory MM, adding lenalidomide to high-dose dexamethasone significantly improves response rates and time-to-progression, relative to high-dose dexamethasone ... See full document

... In the early part of the decade, the combination of thalidomide and dexamethasone emerged as one of the most commonly used induction regimens for the treatment of newly diagnosed myeloma patients. (Rajkumar, 2009) ... See full document

... of multiple myeloma (MM) cells with bone marrow (BM) extracellular matrix (ECM) proteins and BM accessory cells, BM stromal cells (BMSCs), osteoblasts, osteoclasts, endothelial cells, as well as other ... See full document

... careful review of the indirect comparison methods in these four CEAs, the method used to estimate survival from survival curves, potential confounding effects associated with patient baseline characteristics from ... See full document

... Elevated baseline SFLC levels with a steep decline after induction therapy have been associated with poorer progno- sis. This phenomenon was described by Van Rhee et al in 2007. High SFLC levels . 75 mg/dL, and their ... See full document

... in myeloma, approximately 43% of newly diagnosed patients had a response, which is similar to that achieved with ...untreated myeloma patients, in between 65-75 years of age, to receive MP, MD, ... See full document

... Abstract: Multiple myeloma (MM) is the second most common hematologic malignancy in the ...non-secretory multiple myeloma (NSMM) produces no detectable ... See full document

... literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate ... See full document

... diagnosed multiple myeloma, based on paraprotein in serum or urine, bone marrow clonal plasma cells or plasmacytoma, and myeloma­related symptoms or organ or tissue impair­ ...for myeloma (excluding ... See full document

... Multiple myeloma, a cancer of plasma cells, is associated with excessive tumor-induced, osteoclast-mediated bone ...of myeloma in patients, and excessive osteolysis plays a major contributory role in ... See full document

... Copyright © 2018 Prakash Kharel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ... See full document

... reported, multiple myeloma (MM)-associated scleredema is ...smoldering myeloma; and in 1987, Ohta et ...one review) ...smoldering myeloma of ... See full document

... The paradigm of multiple myeloma (MM) therapy has changed dramatically in the past two decades. Immuno- modulatory drugs (IMiDs) including thalidomide and lenalidomide and proteasome inhibitors (PIs) such ... See full document

... Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, ... See full document

... for multiple myeloma oncogene 1 (MUM-1) and ...of multiple myeloma associated with IgA lambda gammopathy confirmed via IFE and immunohistochemical expression of MUM-1 in a ... See full document

... for myeloma cells by inhibiting TRAIL-induced apoptotic cell death (Shipman and ...primary myeloma cells both in vitro and in vivo ...of myeloma cells due to its ability to bypass the inhibition of ... See full document

... A reasonable goal of myeloma treatment in younger “transplant eligible” patients (< 65 years) is to achieve durable CR, and long-term disease control. To achieve this goal, induction therapy with combination ... See full document